Production of clade b, b.63521DELTA11 GP120 ENV protein
Ended Awarded Last action
- Contract number
- HHSN27200024
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,712,780
Award facts
- Contract value 97% obligated
-
- $7,712,779.64 Current, with exercised options
- $7,930,251.64 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $46,812 | |
| Change Order | $84,531 | |
| Change Order | $84,106 | |
| Change Order | $79,856 | |
| Funding Only Action | -$321 | |
| Supplemental Agreement for work within scope | $125,712 | |
| Original award | $7,292,084 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL) for the production of HCMV-TR3ΔPP71 HIVGAG for clinical trials, as part of NIAID's Preclinical Development Support program. The contract has a ceiling value of $7,930,251.64 and a period of performance ending on June 30, 2025. ABL, a for-profit manufacturer of biologics, will provide a range of preclinical and clinical development services, including cGMP manufacturing, process development, analytical testing, and project management. The contract does not have a set-aside designation. ABL has been awarded multiple Indefinite Delivery Vehicles (IDVs) with various NIH institutes, demonstrating its broad capabilities in supporting the development of vaccines, therapeutics, and diagnostics across different disease areas.
Quick answers
Who was awarded contract HHSN27200024?
HHSN27200024 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 26, 2014.
How much is contract HHSN27200024 worth?
The government has obligated $7,712,780 on HHSN27200024. Its potential value, with all options, is $7,930,252.
Is contract HHSN27200024 an order under another contract?
Yes. HHSN27200024 is a delivery order under HHSN272201100021I, an indefinite delivery contract.
Was contract HHSN27200024 competed?
The extent of competition for HHSN27200024 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award